Assignee
ASKAT INC
JP12 patents
Top patents by PatentIndex Score
US10947235B2Mar 16, 2021
Selective EP4 receptor antagonistic substance for treatment of cancer
ASKAT INC3 citations82
US10611761B2Apr 7, 2020
Selective EP4 receptor antagonistic substance for treatment of cancer
ASKAT INC7 citations82
US9447066B2Sep 20, 2016
Salts and crystal forms
ASKAT INC8 citations82
US10583129B2Mar 10, 2020
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
ASKAT INC5 citations79
US10391086B2Aug 27, 2019
Use of EP4 receptor antagonists in the treatment of cartilage disease
ASKAT INC2 citations71
US10342785B2Jul 9, 2019
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
ASKAT INC4 citations68
US12295962B2May 13, 2025
Polymorphic compounds and uses thereof
ASKAT INC0 citations62
US11840530B2Dec 12, 2023
Selective EP4 receptor antagonistic substance for treatment of cancer
ASKAT INC0 citations60
US11964963B2Apr 23, 2024
Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol
ASKAT INC0 citations55
US9561210B2Feb 7, 2017
Therapeutic agent for ocular disease
ASKAT INC0 citations51
US10786490B2Sep 29, 2020
Use of EP4 receptor antagonists in the treatment of cartilage disease
ASKAT INC0 citations50
US11555023B2Jan 17, 2023
Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids
ASKAT INC0 citations36